샘플 요청 목록

 카트 문의
시장보고서
상품코드
1731751

세계의 항염증약 시장

Anti-Inflammatory Drugs
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 488 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 항염증약 시장은 2030년까지 1,670억 달러에 달할 전망

2024년에 1,029억 달러로 추정되는 세계의 항염증약 시장은 2030년에는 1,670억 달러에 달하며, 분석 기간인 2024-2030년의 CAGR은 8.4%로 성장할 것으로 예측됩니다. 이 리포트에서 분석한 부문의 하나인 비스테로이드 항염증약은 CAGR 9.8%를 기록하며, 분석 기간 종료까지 620억 달러에 달할 것으로 예측됩니다. 면역 선택적 항염증 유도체 부문의 성장률은 분석 기간 중 CAGR 9.0%로 추정됩니다.

미국 시장은 추정 280억 달러, 중국은 CAGR 13.3%로 성장 예측

미국의 항염증약시장은 2024년에 280억 달러로 추정됩니다. 세계 2위의 경제대국인 중국은 2030년까지 365억 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년의 CAGR은 13.3%입니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 4.2%와 8.1%로 예측됩니다. 유럽에서는 독일이 CAGR 5.6%로 성장할 것으로 예측됩니다.

세계 항염증약 시장 - 주요 동향 및 촉진요인 정리

항염증약가 광범위한 치료 영역에서 중심적인 중요성을 유지하는 이유는 무엇인가?

항염증약는 관절염, 자가면역질환, 염증성장질환(IBD)에서 심혈관질환, 수술 후 통증, 피부질환에 이르기까지 다양한 급성 및 만성질환에 광범위하게 사용되므로 전 세계 헬스케어에서 매우 중요한 역할을 담당하고 있습니다. 비스테로이드성 항염증약(NSAIDs), 부신피질 스테로이드제, 생물제제, 저분자 억제제로 분류되는 이들 약물은 신체의 염증 경로를 조절하여 통증, 부종, 조직 손상을 완화합니다. 염증은 많은 질병에 공통적으로 나타나기 때문에 류마티스내과, 종양내과, 소화기내과, 호흡기내과, 피부과, 일반내과 등 여러 전문 분야에 걸쳐 항염증 치료는 필수적입니다.

항염증약의 임상적 유용성은 경구, 국소, 국소, 주사, 정맥 투여와 같은 유연한 투여 방법과 급성기 치료 및 장기적인 질병 관리 모두에 대한 적합성으로 인해 강화되고 있습니다. 이부프로펜, 나프록센, 디클로페낙과 같은 비스테로이드성 항염증약(NSAIDs)는 여전히 일반의약품 및 처방약 분야에서 주류이며, 프레드니손과 덱사메타손과 같은 부신피질 스테로이드는 전신적인 염증 조절에 필수적입니다. 만성 염증성 질환의 부담은 전 세계에서 증가하고 있으며, 특히 고령화 사회와 좌식 생활습관으로 인해 약리학적 항염증약에 대한 장기적인 수요를 지원하고 있습니다. 또한 COVID-19와 같은 세계 보건 위기는 심각한 호흡기 질환 및 사이토카인 매개 합병증 치료에 있으며, 덱사메타손과 같은 부신피질 스테로이드의 중요성을 더욱 강조하고, 응급의료 및 치료 프로토콜에서 그 중요성을 재확인하고 있습니다.

새로운 생물제제와 표적 억제제는 항염증약의 전망을 어떻게 재정의하고 있는가?

항염증약 시장의 큰 변화는 기존 항염증약에 비해 표적 특이성이 높고 전신 부작용이 적은 생물제제, 모노클로널 항체, 저분자 억제제의 등장으로 이루어지고 있습니다. 이들 차세대 치료제는 만성 염증을 유발하는 염증성 사이토카인(TNF-α, IL-1, IL-6 등), 세포 표면 마커, 세포내 신호전달 경로(JAK-STAT, NF-kB 등)를 억제하도록 설계되어 있습니다. 아달리무맙, 에타너셉트, 토파시티닙, 우스테키누맙 등의 치료제는 류마티스 관절염, 건선, 강직성 척추염, 궤양성 대장염 등의 치료를 재구성하여 지속적인 관해와 환자의 삶의 질 향상을 가져오고 있습니다.

서방형 주사제, 피하 자가주사제, 표적 경구용 캡슐을 포함한 약물전달 시스템의 혁신은 편의성, 순응도, 생체 이용률을 향상시키고 있습니다. 바이오시밀러는 특히 비용에 민감한 시장에서 부상하고 있으며, 규제 당국의 승인이 진행됨에 따라 고가의 생물제제에 대한 폭넓은 접근이 가능해졌습니다. 이와 함께 숙주-병원체 상호작용, 장내세균총 조절, 면역 체크포인트 조절 등의 연구로 항염증약의 치료 범위가 신경염증, 암 면역치료, 대사성 질환 등의 영역으로 확대되고 있습니다. 이러한 발전으로 시장은 대증요법에서 분자 수준에서 염증을 차단할 수 있는 질병 조절 전략으로 이동하고 있으며, 개인맞춤의료와 정밀의료의 새로운 지평을 열어가고 있습니다.

시장 성장이 가속화되는 곳은 어디이며, 어떤 치료 영역이 수요를 촉진하고 있는가?

항염증약 시장은 북미, 유럽, 아시아태평양에서 강력한 성장세를 보이고 있으며, 염증성 질환의 높은 유병률, 진단 능력의 확대, 치료 가이드라인의 진화에 힘입어 성장하고 있습니다. 북미는 탄탄한 의료 인프라, 첨단 생물제제, 높은 처방량 등에 힘입어 여전히 지배적인 시장으로 남아 있습니다. 아시아태평양에서는 급속한 도시화, 중산층의 의료비 증가, 자가면역질환 및 만성 염증성 질환 증가로 인해 중국, 일본, 인도, 한국 등지에서 도입이 가속화되고 있습니다.

류마티스내과(류마티스 관절염, 통풍), 소화기내과(크론병, 궤양성 대장염), 피부과(습진, 건선), 호흡기내과(천식, COPD), 신경과(다발성 경화증, 신경염증성 질환) 등이 수요를 견인하는 치료 분야입니다. 종양학에서 항염증약는 치료에 의해 유발된 염증을 관리하고 종양을 촉진하는 염증에 대항하는 새로운 전략의 일환으로 보조적으로 사용되고 있습니다. 정형외과, 외상 치료, 스포츠 의학도 NSAIDs와 코르티코스테로이드를 많이 사용하는 분야입니다. 소아과 영역에서는 소아청소년 특발성 관절염 및 기타 희귀한 자가 염증성 증후군이 증가하고 있으며, 여성 의료 영역에서는 자궁내막증과 같은 질환이 확대되고 있습니다. 이러한 광범위한 적응증으로 인해 항염증약는 전문 의료와 1차 의료 모두에서 필수적인 역할을 하고 있습니다.

항염증약 세계 시장 지속 확대의 원동력은?

항염증약 시장의 성장은 만성 염증성 질환의 유병률 증가, 첨단 생물제제의 지속적인 채택, 정밀 표적 치료의 출현 등 여러 요인에 의해 주도되고 있습니다. 주요 촉진요인은 관절염, 심혈관 염증, 자가면역질환에 취약한 세계 인구의 고령화이며, 이로 인해 장기적인 약물 수요를 증가시키고 있습니다. 질병 모니터링 툴와 바이오마커를 기반으로 한 진단의 발전은 의사들이 전신 부작용을 최소화하고 치료의 정확성을 극대화하는 표적화된 항염증 중재를 채택하도록 유도하여 보다 빠르고 정확한 치료를 가능하게 하고 있습니다.

제네릭과 바이오시밀러의 보급과 함께 신흥 시장에서의 의료 접근성이 확대되고 비용 장벽이 낮아지면서 필수적인 항염증약에 대한 환자 접근성이 확대되고 있습니다. 염증에 특화된 파이프라인, 전략적 파트너십, 시판 후 조사에 대한 제약사의 투자는 임상적 신뢰와 시장 안정성을 더욱 높여주고 있습니다. 한편, 소비자들의 천연 항염증약 및 보조 항염증약에 대한 선호도가 높아짐에 따라 염증 조절 작용을 하는 식물화학물질, 건강기능식품, 통합요법에 대한 연구개발이 진행되고 있습니다. 염증이 다양한 병태생리에서 핵심적인 요소로 인식되면서 매우 중요한 의문이 제기되고 있습니다. 항염증약의 기술 혁신이 질병의 복잡성을 계속 능가하고, 전신 질환과 장기 특이적 질환 모두에서 확장 가능하고 장기적인 해결책을 제공할 수 있는가?

부문

약제 유형(비스테로이드계 항염증약, 면역 선택적 항염증 유도체, 항염증 생물제제, 부신피질 스테로이드), 용도(관절염, 만성폐쇄성폐질환, 다발성 경화증, 염증성장질환, 통풍, 기타 용도), 투여 경로(경구, 국소, 주사, 흡입), 유통 채널(병원 약국, 소매 약국, 온라인 약국)

조사 대상 기업의 예(주목 44사)

  • AbbVie Inc.
  • Abivax SA
  • Amgen Inc.
  • AstraZeneca plc
  • Bayer AG
  • Biogen Inc.
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc(GSK)
  • Glenmark Pharmaceuticals Ltd.
  • Incyte Corporation
  • Johnson & Johnson
  • Lupin Limited
  • Merck & Co., Inc.
  • Mylan N.V.

관세 영향 계수

Global Industry Analysts는 본국, 제조거점, 수출입(완제품 및 OEM)을 기반으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 인위적인 수입원가 증가, 수익성 하락, 공급망 재편 등 미시적 및 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

Global Industry Analysts는 세계 주요 수석 이코노미스트(1,4,949명), 싱크탱크(62개 기관), 무역 및 산업 단체(171개 기관)의 전문가들의 의견을 면밀히 검토하여 생태계에 미치는 영향을 평가하고 새로운 시장 현실에 대응하고 있습니다. 모든 주요 국가의 전문가와 경제학자들이 관세와 그것이 자국에 미치는 영향에 대한 의견을 추적 조사했습니다.

Global Industry Analysts는 이러한 혼란이 향후 2-3개월 내에 마무리되고 새로운 세계 질서가 보다 명확하게 확립될 것으로 예상하고 있으며, Global Industry Analysts는 이러한 상황을 실시간으로 추적하고 있습니다.

2025년 4월: 협상 단계

이번 4월 보고서에서는 관세가 세계 시장 전체에 미치는 영향과 지역별 시장 조정에 대해 소개합니다. 당사의 예측은 과거 데이터와 진화하는 시장 영향요인을 기반으로 합니다.

2025년 7월: 최종 관세 재설정

무료 업데이트 각국의 최종 리셋이 발표된 후, 7월에 무료 업데이트 버전을 고객님들께 제공해 드립니다. 최종 업데이트 버전에는 명확하게 정의된 관세 영향 분석이 포함되어 있습니다.

상호 및 양자 간 무역과 관세의 영향 분석 :

미국 <>중국 <>멕시코 <>캐나다 <>EU <>일본 <>인도 <>기타 176개국

업계 최고의 이코노미스트: Global Industry Analysts의 지식 기반은 국가, 싱크탱크, 무역 및 산업 단체, 대기업, 그리고 세계 계량 경제 상황의 전례 없는 패러다임 전환의 영향을 공유하는 분야별 전문가 등 가장 영향력 있는 수석 이코노미스트를 포함한 14,949명의 이코노미스트를 추적하고 있습니다. 16,491개 이상의 보고서 대부분에 마일스톤에 기반한 2단계 출시 일정이 적용되어 있습니다.

목차

제1장 조사 방법

제2장 개요

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSA 25.06.13

Global Anti-Inflammatory Drugs Market to Reach US$167.0 Billion by 2030

The global market for Anti-Inflammatory Drugs estimated at US$102.9 Billion in the year 2024, is expected to reach US$167.0 Billion by 2030, growing at a CAGR of 8.4% over the analysis period 2024-2030. Nonsteroidal Anti-inflammatory Drugs, one of the segments analyzed in the report, is expected to record a 9.8% CAGR and reach US$62.0 Billion by the end of the analysis period. Growth in the Immune Selective Anti-inflammatory Derivatives segment is estimated at 9.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$28.0 Billion While China is Forecast to Grow at 13.3% CAGR

The Anti-Inflammatory Drugs market in the U.S. is estimated at US$28.0 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$36.5 Billion by the year 2030 trailing a CAGR of 13.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.2% and 8.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.6% CAGR.

Global Anti-Inflammatory Drugs Market - Key Trends & Drivers Summarized

Why Are Anti-Inflammatory Drugs Retaining Central Importance Across a Broad Therapeutic Spectrum?

Anti-inflammatory drugs continue to hold a pivotal role in global healthcare, owing to their widespread use across a diverse array of acute and chronic conditions-ranging from arthritis, autoimmune diseases, and inflammatory bowel disease (IBD) to cardiovascular disorders, post-operative pain, and dermatological conditions. These drugs-classified into nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and emerging biologics and small-molecule inhibitors-modulate the body’s inflammatory pathways to alleviate pain, swelling, and tissue damage. As inflammation is a common denominator in numerous diseases, anti-inflammatory therapies remain essential across specialties such as rheumatology, oncology, gastroenterology, pulmonology, dermatology, and general medicine.

Their clinical utility is reinforced by their flexibility in administration-oral, topical, injectable, or intravenous-and compatibility with both acute interventions and long-term disease management. NSAIDs like ibuprofen, naproxen, and diclofenac remain mainstays in over-the-counter and prescription segments, while corticosteroids such as prednisone and dexamethasone are essential in systemic inflammation control. The burden of chronic inflammatory conditions is increasing globally, particularly in aging populations and sedentary lifestyles, sustaining long-term demand for pharmacological anti-inflammatories. In addition, global health crises such as COVID-19 have further emphasized the importance of anti-inflammatory drugs-particularly corticosteroids like dexamethasone-in managing severe respiratory and cytokine-mediated complications, reaffirming their relevance in emergency care and treatment protocols.

How Are Novel Biologics and Targeted Inhibitors Redefining the Anti-Inflammatory Drug Landscape?

A significant transformation in the anti-inflammatory drug market is being driven by the rise of biologics, monoclonal antibodies, and small-molecule inhibitors that offer greater target specificity and reduced systemic side effects compared to traditional anti-inflammatory agents. These next-generation therapies are designed to inhibit pro-inflammatory cytokines (e.g., TNF-α, IL-1, IL-6), cell surface markers, and intracellular signaling pathways (e.g., JAK-STAT, NF-kB) responsible for chronic inflammation. Drugs such as adalimumab, etanercept, tofacitinib, and ustekinumab have reshaped the treatment of rheumatoid arthritis, psoriasis, ankylosing spondylitis, and ulcerative colitis, offering sustained remission and improved patient quality of life.

Technological innovation in drug delivery systems-including extended-release injectables, subcutaneous self-injectors, and targeted oral capsules-is enhancing convenience, adherence, and bioavailability. Biosimilars are also gaining ground, especially in cost-sensitive markets, with increased regulatory approvals enabling broader access to high-cost biologics. In parallel, research into host-pathogen interaction, gut microbiome modulation, and immune checkpoint regulation is expanding the therapeutic scope of anti-inflammatory drugs into areas such as neuroinflammation, cancer immunotherapy, and metabolic disorders. These developments are shifting the market from symptomatic control to disease-modifying strategies that can intercept inflammation at a molecular level, unlocking new frontiers in personalized and precision medicine.

Where Is Market Growth Accelerating and Which Therapeutic Areas Are Fueling Demand?

The anti-inflammatory drugs market is experiencing strong growth across North America, Europe, and Asia-Pacific, driven by high prevalence of inflammatory conditions, expanded diagnostic capabilities, and evolving treatment guidelines. North America remains the dominant market, underpinned by robust healthcare infrastructure, advanced biologic therapies, and high prescription volumes. Europe follows closely, supported by universal healthcare systems, aging populations, and increased uptake of biosimilars, especially in markets like Germany and the U.K. In Asia-Pacific, rapid urbanization, growing middle-class healthcare expenditure, and increased detection of autoimmune and chronic inflammatory diseases are accelerating adoption-particularly in China, Japan, India, and South Korea.

Therapeutic areas fueling demand include rheumatology (rheumatoid arthritis, gout), gastroenterology (Crohn’s disease, ulcerative colitis), dermatology (eczema, psoriasis), respiratory care (asthma, COPD), and neurology (multiple sclerosis, neuroinflammatory disorders). In oncology, anti-inflammatory agents are being used adjunctively to manage treatment-induced inflammation and as part of emerging strategies to counteract tumor-promoting inflammation. Orthopedic surgery, trauma care, and sports medicine also constitute high-usage areas for NSAIDs and corticosteroids. The pediatric segment is witnessing growth in juvenile idiopathic arthritis and other rare autoinflammatory syndromes, while women’s health applications are expanding for conditions like endometriosis. These broad indications ensure that anti-inflammatory drugs remain integral across both specialized and primary care settings.

What Is Driving the Continued Expansion of the Global Anti-Inflammatory Drugs Market?

The growth in the anti-inflammatory drugs market is driven by several factors, including rising incidence of chronic inflammatory diseases, sustained adoption of advanced biologics, and the emergence of precision-targeted therapies. A key driver is the aging global population, which is more susceptible to arthritis, cardiovascular inflammation, and autoimmune conditions-thereby increasing long-term medication demand. Advancements in disease monitoring tools and biomarker-based diagnosis are facilitating earlier and more accurate treatment, pushing physicians to adopt targeted anti-inflammatory interventions that minimize systemic side effects and maximize therapeutic precision.

Expanding access to healthcare in emerging markets, coupled with generic and biosimilar penetration, is lowering cost barriers and broadening patient access to essential anti-inflammatories. Investment from pharmaceutical companies in inflammation-focused pipelines, strategic partnerships, and post-marketing surveillance is further enhancing clinical confidence and market stability. Meanwhile, consumer preference for natural or adjunctive anti-inflammatory solutions is prompting R&D into phytochemicals, dietary supplements, and integrative therapies with inflammation-modulating properties. With inflammation increasingly recognized as a central component in diverse pathologies, a pivotal question arises: Can anti-inflammatory drug innovation continue to outpace disease complexity and deliver scalable, long-term solutions across both systemic and organ-specific disorders?

SCOPE OF STUDY:

The report analyzes the Anti-Inflammatory Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Type (Nonsteroidal Anti-inflammatory Drugs, Immune Selective Anti-inflammatory Derivatives, Anti-inflammatory Biologics, Corticosteroids); Application (Arthritis, Chronic Obstructive Pulmonary Disease, Multiple Sclerosis, Inflammatory Bowel Disease, Gout, Other Applications); Administration Route (Oral, Topical, Injection, Inhalation); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

  • AbbVie Inc.
  • Abivax SA
  • Amgen Inc.
  • AstraZeneca plc
  • Bayer AG
  • Biogen Inc.
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc (GSK)
  • Glenmark Pharmaceuticals Ltd.
  • Incyte Corporation
  • Johnson & Johnson
  • Lupin Limited
  • Merck & Co., Inc.
  • Mylan N.V.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Anti-Inflammatory Drugs - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Expanding Burden of Chronic Inflammatory Conditions Reinforces Market Need for Anti-Inflammatory Drugs
    • Over-the-Counter Accessibility Sustains Widespread Use of Non-Prescription Anti-Inflammatory Drugs
    • Biologics and Targeted Small Molecules Redefine the Competitive Edge in Anti-Inflammatory Drug Development
    • Sports Injuries and Musculoskeletal Disorders Increase Demand for Rapid-Relief Anti-Inflammatory Drugs
    • Integration into Multimodal Pain Management Protocols Enhances Utility of Anti-Inflammatory Drugs
    • Regulatory Approvals for Novel Formulations and Combinations Strengthen Market Penetration
    • Aging Population Spurs Sustained Use of Anti-Inflammatory Drugs for Joint and Mobility Disorders
    • Consumer Shift Toward Topical and Gastro-Friendly Formats Spurs Innovation in Anti-Inflammatory Drugs
    • Clinical Guidelines Endorsing Early Use of Anti-Inflammatory Drugs Improve Treatment Adherence
    • Awareness Campaigns Around Autoimmune Diseases Expand Market Reach of Anti-Inflammatory Drugs
    • Personalized Medicine Approaches Encourage Tailored Use of Anti-Inflammatory Drug Therapies
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Anti-Inflammatory Drugs Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Anti-Inflammatory Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Anti-Inflammatory Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Nonsteroidal Anti-inflammatory Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Nonsteroidal Anti-inflammatory Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Nonsteroidal Anti-inflammatory Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Immune Selective Anti-inflammatory Derivatives by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Immune Selective Anti-inflammatory Derivatives by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Immune Selective Anti-inflammatory Derivatives by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Anti-inflammatory Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Anti-inflammatory Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Anti-inflammatory Biologics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Corticosteroids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Arthritis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Arthritis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Arthritis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Chronic Obstructive Pulmonary Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Chronic Obstructive Pulmonary Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Multiple Sclerosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Multiple Sclerosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Multiple Sclerosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Inflammatory Bowel Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Inflammatory Bowel Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Inflammatory Bowel Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Gout by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Gout by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for Gout by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: World 15-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Topical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Topical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: World 15-Year Perspective for Topical by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 41: World Recent Past, Current & Future Analysis for Injection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 42: World Historic Review for Injection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: World 15-Year Perspective for Injection by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 44: World Recent Past, Current & Future Analysis for Inhalation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 45: World Historic Review for Inhalation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: World 15-Year Perspective for Inhalation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 47: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 48: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 50: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 51: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: World 15-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 53: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 54: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: World 15-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Anti-Inflammatory Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 56: USA Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Drug Type - Nonsteroidal Anti-inflammatory Drugs, Immune Selective Anti-inflammatory Derivatives, Anti-inflammatory Biologics and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: USA Historic Review for Anti-Inflammatory Drugs by Drug Type - Nonsteroidal Anti-inflammatory Drugs, Immune Selective Anti-inflammatory Derivatives, Anti-inflammatory Biologics and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: USA 15-Year Perspective for Anti-Inflammatory Drugs by Drug Type - Percentage Breakdown of Value Sales for Nonsteroidal Anti-inflammatory Drugs, Immune Selective Anti-inflammatory Derivatives, Anti-inflammatory Biologics and Corticosteroids for the Years 2015, 2025 & 2030
    • TABLE 59: USA Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Application - Other Applications, Arthritis, Chronic Obstructive Pulmonary Disease, Multiple Sclerosis, Inflammatory Bowel Disease and Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: USA Historic Review for Anti-Inflammatory Drugs by Application - Other Applications, Arthritis, Chronic Obstructive Pulmonary Disease, Multiple Sclerosis, Inflammatory Bowel Disease and Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: USA 15-Year Perspective for Anti-Inflammatory Drugs by Application - Percentage Breakdown of Value Sales for Other Applications, Arthritis, Chronic Obstructive Pulmonary Disease, Multiple Sclerosis, Inflammatory Bowel Disease and Gout for the Years 2015, 2025 & 2030
    • TABLE 62: USA Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Administration Route - Oral, Topical, Injection and Inhalation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: USA Historic Review for Anti-Inflammatory Drugs by Administration Route - Oral, Topical, Injection and Inhalation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: USA 15-Year Perspective for Anti-Inflammatory Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Injection and Inhalation for the Years 2015, 2025 & 2030
    • TABLE 65: USA Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: USA Historic Review for Anti-Inflammatory Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: USA 15-Year Perspective for Anti-Inflammatory Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 68: Canada Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Drug Type - Nonsteroidal Anti-inflammatory Drugs, Immune Selective Anti-inflammatory Derivatives, Anti-inflammatory Biologics and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Canada Historic Review for Anti-Inflammatory Drugs by Drug Type - Nonsteroidal Anti-inflammatory Drugs, Immune Selective Anti-inflammatory Derivatives, Anti-inflammatory Biologics and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Canada 15-Year Perspective for Anti-Inflammatory Drugs by Drug Type - Percentage Breakdown of Value Sales for Nonsteroidal Anti-inflammatory Drugs, Immune Selective Anti-inflammatory Derivatives, Anti-inflammatory Biologics and Corticosteroids for the Years 2015, 2025 & 2030
    • TABLE 71: Canada Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Application - Other Applications, Arthritis, Chronic Obstructive Pulmonary Disease, Multiple Sclerosis, Inflammatory Bowel Disease and Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Canada Historic Review for Anti-Inflammatory Drugs by Application - Other Applications, Arthritis, Chronic Obstructive Pulmonary Disease, Multiple Sclerosis, Inflammatory Bowel Disease and Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Canada 15-Year Perspective for Anti-Inflammatory Drugs by Application - Percentage Breakdown of Value Sales for Other Applications, Arthritis, Chronic Obstructive Pulmonary Disease, Multiple Sclerosis, Inflammatory Bowel Disease and Gout for the Years 2015, 2025 & 2030
    • TABLE 74: Canada Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Administration Route - Oral, Topical, Injection and Inhalation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Canada Historic Review for Anti-Inflammatory Drugs by Administration Route - Oral, Topical, Injection and Inhalation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Canada 15-Year Perspective for Anti-Inflammatory Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Injection and Inhalation for the Years 2015, 2025 & 2030
    • TABLE 77: Canada Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Canada Historic Review for Anti-Inflammatory Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Canada 15-Year Perspective for Anti-Inflammatory Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • JAPAN
    • Anti-Inflammatory Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 80: Japan Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Drug Type - Nonsteroidal Anti-inflammatory Drugs, Immune Selective Anti-inflammatory Derivatives, Anti-inflammatory Biologics and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Japan Historic Review for Anti-Inflammatory Drugs by Drug Type - Nonsteroidal Anti-inflammatory Drugs, Immune Selective Anti-inflammatory Derivatives, Anti-inflammatory Biologics and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Japan 15-Year Perspective for Anti-Inflammatory Drugs by Drug Type - Percentage Breakdown of Value Sales for Nonsteroidal Anti-inflammatory Drugs, Immune Selective Anti-inflammatory Derivatives, Anti-inflammatory Biologics and Corticosteroids for the Years 2015, 2025 & 2030
    • TABLE 83: Japan Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Application - Other Applications, Arthritis, Chronic Obstructive Pulmonary Disease, Multiple Sclerosis, Inflammatory Bowel Disease and Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Japan Historic Review for Anti-Inflammatory Drugs by Application - Other Applications, Arthritis, Chronic Obstructive Pulmonary Disease, Multiple Sclerosis, Inflammatory Bowel Disease and Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Japan 15-Year Perspective for Anti-Inflammatory Drugs by Application - Percentage Breakdown of Value Sales for Other Applications, Arthritis, Chronic Obstructive Pulmonary Disease, Multiple Sclerosis, Inflammatory Bowel Disease and Gout for the Years 2015, 2025 & 2030
    • TABLE 86: Japan Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Administration Route - Oral, Topical, Injection and Inhalation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Japan Historic Review for Anti-Inflammatory Drugs by Administration Route - Oral, Topical, Injection and Inhalation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Japan 15-Year Perspective for Anti-Inflammatory Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Injection and Inhalation for the Years 2015, 2025 & 2030
    • TABLE 89: Japan Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Japan Historic Review for Anti-Inflammatory Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Japan 15-Year Perspective for Anti-Inflammatory Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • CHINA
    • Anti-Inflammatory Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 92: China Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Drug Type - Nonsteroidal Anti-inflammatory Drugs, Immune Selective Anti-inflammatory Derivatives, Anti-inflammatory Biologics and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: China Historic Review for Anti-Inflammatory Drugs by Drug Type - Nonsteroidal Anti-inflammatory Drugs, Immune Selective Anti-inflammatory Derivatives, Anti-inflammatory Biologics and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: China 15-Year Perspective for Anti-Inflammatory Drugs by Drug Type - Percentage Breakdown of Value Sales for Nonsteroidal Anti-inflammatory Drugs, Immune Selective Anti-inflammatory Derivatives, Anti-inflammatory Biologics and Corticosteroids for the Years 2015, 2025 & 2030
    • TABLE 95: China Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Application - Other Applications, Arthritis, Chronic Obstructive Pulmonary Disease, Multiple Sclerosis, Inflammatory Bowel Disease and Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: China Historic Review for Anti-Inflammatory Drugs by Application - Other Applications, Arthritis, Chronic Obstructive Pulmonary Disease, Multiple Sclerosis, Inflammatory Bowel Disease and Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: China 15-Year Perspective for Anti-Inflammatory Drugs by Application - Percentage Breakdown of Value Sales for Other Applications, Arthritis, Chronic Obstructive Pulmonary Disease, Multiple Sclerosis, Inflammatory Bowel Disease and Gout for the Years 2015, 2025 & 2030
    • TABLE 98: China Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Administration Route - Oral, Topical, Injection and Inhalation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: China Historic Review for Anti-Inflammatory Drugs by Administration Route - Oral, Topical, Injection and Inhalation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: China 15-Year Perspective for Anti-Inflammatory Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Injection and Inhalation for the Years 2015, 2025 & 2030
    • TABLE 101: China Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: China Historic Review for Anti-Inflammatory Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: China 15-Year Perspective for Anti-Inflammatory Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • EUROPE
    • Anti-Inflammatory Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 104: Europe Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 105: Europe Historic Review for Anti-Inflammatory Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Europe 15-Year Perspective for Anti-Inflammatory Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 107: Europe Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Drug Type - Nonsteroidal Anti-inflammatory Drugs, Immune Selective Anti-inflammatory Derivatives, Anti-inflammatory Biologics and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Europe Historic Review for Anti-Inflammatory Drugs by Drug Type - Nonsteroidal Anti-inflammatory Drugs, Immune Selective Anti-inflammatory Derivatives, Anti-inflammatory Biologics and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Europe 15-Year Perspective for Anti-Inflammatory Drugs by Drug Type - Percentage Breakdown of Value Sales for Nonsteroidal Anti-inflammatory Drugs, Immune Selective Anti-inflammatory Derivatives, Anti-inflammatory Biologics and Corticosteroids for the Years 2015, 2025 & 2030
    • TABLE 110: Europe Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Application - Other Applications, Arthritis, Chronic Obstructive Pulmonary Disease, Multiple Sclerosis, Inflammatory Bowel Disease and Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Europe Historic Review for Anti-Inflammatory Drugs by Application - Other Applications, Arthritis, Chronic Obstructive Pulmonary Disease, Multiple Sclerosis, Inflammatory Bowel Disease and Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Europe 15-Year Perspective for Anti-Inflammatory Drugs by Application - Percentage Breakdown of Value Sales for Other Applications, Arthritis, Chronic Obstructive Pulmonary Disease, Multiple Sclerosis, Inflammatory Bowel Disease and Gout for the Years 2015, 2025 & 2030
    • TABLE 113: Europe Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Administration Route - Oral, Topical, Injection and Inhalation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Europe Historic Review for Anti-Inflammatory Drugs by Administration Route - Oral, Topical, Injection and Inhalation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Europe 15-Year Perspective for Anti-Inflammatory Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Injection and Inhalation for the Years 2015, 2025 & 2030
    • TABLE 116: Europe Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Europe Historic Review for Anti-Inflammatory Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: Europe 15-Year Perspective for Anti-Inflammatory Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • FRANCE
    • Anti-Inflammatory Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 119: France Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Drug Type - Nonsteroidal Anti-inflammatory Drugs, Immune Selective Anti-inflammatory Derivatives, Anti-inflammatory Biologics and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: France Historic Review for Anti-Inflammatory Drugs by Drug Type - Nonsteroidal Anti-inflammatory Drugs, Immune Selective Anti-inflammatory Derivatives, Anti-inflammatory Biologics and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: France 15-Year Perspective for Anti-Inflammatory Drugs by Drug Type - Percentage Breakdown of Value Sales for Nonsteroidal Anti-inflammatory Drugs, Immune Selective Anti-inflammatory Derivatives, Anti-inflammatory Biologics and Corticosteroids for the Years 2015, 2025 & 2030
    • TABLE 122: France Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Application - Other Applications, Arthritis, Chronic Obstructive Pulmonary Disease, Multiple Sclerosis, Inflammatory Bowel Disease and Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: France Historic Review for Anti-Inflammatory Drugs by Application - Other Applications, Arthritis, Chronic Obstructive Pulmonary Disease, Multiple Sclerosis, Inflammatory Bowel Disease and Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: France 15-Year Perspective for Anti-Inflammatory Drugs by Application - Percentage Breakdown of Value Sales for Other Applications, Arthritis, Chronic Obstructive Pulmonary Disease, Multiple Sclerosis, Inflammatory Bowel Disease and Gout for the Years 2015, 2025 & 2030
    • TABLE 125: France Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Administration Route - Oral, Topical, Injection and Inhalation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: France Historic Review for Anti-Inflammatory Drugs by Administration Route - Oral, Topical, Injection and Inhalation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: France 15-Year Perspective for Anti-Inflammatory Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Injection and Inhalation for the Years 2015, 2025 & 2030
    • TABLE 128: France Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: France Historic Review for Anti-Inflammatory Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: France 15-Year Perspective for Anti-Inflammatory Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • GERMANY
    • Anti-Inflammatory Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 131: Germany Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Drug Type - Nonsteroidal Anti-inflammatory Drugs, Immune Selective Anti-inflammatory Derivatives, Anti-inflammatory Biologics and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Germany Historic Review for Anti-Inflammatory Drugs by Drug Type - Nonsteroidal Anti-inflammatory Drugs, Immune Selective Anti-inflammatory Derivatives, Anti-inflammatory Biologics and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Germany 15-Year Perspective for Anti-Inflammatory Drugs by Drug Type - Percentage Breakdown of Value Sales for Nonsteroidal Anti-inflammatory Drugs, Immune Selective Anti-inflammatory Derivatives, Anti-inflammatory Biologics and Corticosteroids for the Years 2015, 2025 & 2030
    • TABLE 134: Germany Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Application - Other Applications, Arthritis, Chronic Obstructive Pulmonary Disease, Multiple Sclerosis, Inflammatory Bowel Disease and Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Germany Historic Review for Anti-Inflammatory Drugs by Application - Other Applications, Arthritis, Chronic Obstructive Pulmonary Disease, Multiple Sclerosis, Inflammatory Bowel Disease and Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Germany 15-Year Perspective for Anti-Inflammatory Drugs by Application - Percentage Breakdown of Value Sales for Other Applications, Arthritis, Chronic Obstructive Pulmonary Disease, Multiple Sclerosis, Inflammatory Bowel Disease and Gout for the Years 2015, 2025 & 2030
    • TABLE 137: Germany Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Administration Route - Oral, Topical, Injection and Inhalation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Germany Historic Review for Anti-Inflammatory Drugs by Administration Route - Oral, Topical, Injection and Inhalation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Germany 15-Year Perspective for Anti-Inflammatory Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Injection and Inhalation for the Years 2015, 2025 & 2030
    • TABLE 140: Germany Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Germany Historic Review for Anti-Inflammatory Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Germany 15-Year Perspective for Anti-Inflammatory Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 143: Italy Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Drug Type - Nonsteroidal Anti-inflammatory Drugs, Immune Selective Anti-inflammatory Derivatives, Anti-inflammatory Biologics and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Italy Historic Review for Anti-Inflammatory Drugs by Drug Type - Nonsteroidal Anti-inflammatory Drugs, Immune Selective Anti-inflammatory Derivatives, Anti-inflammatory Biologics and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Italy 15-Year Perspective for Anti-Inflammatory Drugs by Drug Type - Percentage Breakdown of Value Sales for Nonsteroidal Anti-inflammatory Drugs, Immune Selective Anti-inflammatory Derivatives, Anti-inflammatory Biologics and Corticosteroids for the Years 2015, 2025 & 2030
    • TABLE 146: Italy Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Application - Other Applications, Arthritis, Chronic Obstructive Pulmonary Disease, Multiple Sclerosis, Inflammatory Bowel Disease and Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Italy Historic Review for Anti-Inflammatory Drugs by Application - Other Applications, Arthritis, Chronic Obstructive Pulmonary Disease, Multiple Sclerosis, Inflammatory Bowel Disease and Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Italy 15-Year Perspective for Anti-Inflammatory Drugs by Application - Percentage Breakdown of Value Sales for Other Applications, Arthritis, Chronic Obstructive Pulmonary Disease, Multiple Sclerosis, Inflammatory Bowel Disease and Gout for the Years 2015, 2025 & 2030
    • TABLE 149: Italy Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Administration Route - Oral, Topical, Injection and Inhalation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Italy Historic Review for Anti-Inflammatory Drugs by Administration Route - Oral, Topical, Injection and Inhalation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Italy 15-Year Perspective for Anti-Inflammatory Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Injection and Inhalation for the Years 2015, 2025 & 2030
    • TABLE 152: Italy Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Italy Historic Review for Anti-Inflammatory Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Italy 15-Year Perspective for Anti-Inflammatory Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Anti-Inflammatory Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 155: UK Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Drug Type - Nonsteroidal Anti-inflammatory Drugs, Immune Selective Anti-inflammatory Derivatives, Anti-inflammatory Biologics and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: UK Historic Review for Anti-Inflammatory Drugs by Drug Type - Nonsteroidal Anti-inflammatory Drugs, Immune Selective Anti-inflammatory Derivatives, Anti-inflammatory Biologics and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: UK 15-Year Perspective for Anti-Inflammatory Drugs by Drug Type - Percentage Breakdown of Value Sales for Nonsteroidal Anti-inflammatory Drugs, Immune Selective Anti-inflammatory Derivatives, Anti-inflammatory Biologics and Corticosteroids for the Years 2015, 2025 & 2030
    • TABLE 158: UK Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Application - Other Applications, Arthritis, Chronic Obstructive Pulmonary Disease, Multiple Sclerosis, Inflammatory Bowel Disease and Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: UK Historic Review for Anti-Inflammatory Drugs by Application - Other Applications, Arthritis, Chronic Obstructive Pulmonary Disease, Multiple Sclerosis, Inflammatory Bowel Disease and Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: UK 15-Year Perspective for Anti-Inflammatory Drugs by Application - Percentage Breakdown of Value Sales for Other Applications, Arthritis, Chronic Obstructive Pulmonary Disease, Multiple Sclerosis, Inflammatory Bowel Disease and Gout for the Years 2015, 2025 & 2030
    • TABLE 161: UK Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Administration Route - Oral, Topical, Injection and Inhalation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: UK Historic Review for Anti-Inflammatory Drugs by Administration Route - Oral, Topical, Injection and Inhalation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: UK 15-Year Perspective for Anti-Inflammatory Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Injection and Inhalation for the Years 2015, 2025 & 2030
    • TABLE 164: UK Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: UK Historic Review for Anti-Inflammatory Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: UK 15-Year Perspective for Anti-Inflammatory Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 167: Spain Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Drug Type - Nonsteroidal Anti-inflammatory Drugs, Immune Selective Anti-inflammatory Derivatives, Anti-inflammatory Biologics and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Spain Historic Review for Anti-Inflammatory Drugs by Drug Type - Nonsteroidal Anti-inflammatory Drugs, Immune Selective Anti-inflammatory Derivatives, Anti-inflammatory Biologics and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Spain 15-Year Perspective for Anti-Inflammatory Drugs by Drug Type - Percentage Breakdown of Value Sales for Nonsteroidal Anti-inflammatory Drugs, Immune Selective Anti-inflammatory Derivatives, Anti-inflammatory Biologics and Corticosteroids for the Years 2015, 2025 & 2030
    • TABLE 170: Spain Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Application - Other Applications, Arthritis, Chronic Obstructive Pulmonary Disease, Multiple Sclerosis, Inflammatory Bowel Disease and Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Spain Historic Review for Anti-Inflammatory Drugs by Application - Other Applications, Arthritis, Chronic Obstructive Pulmonary Disease, Multiple Sclerosis, Inflammatory Bowel Disease and Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Spain 15-Year Perspective for Anti-Inflammatory Drugs by Application - Percentage Breakdown of Value Sales for Other Applications, Arthritis, Chronic Obstructive Pulmonary Disease, Multiple Sclerosis, Inflammatory Bowel Disease and Gout for the Years 2015, 2025 & 2030
    • TABLE 173: Spain Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Administration Route - Oral, Topical, Injection and Inhalation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Spain Historic Review for Anti-Inflammatory Drugs by Administration Route - Oral, Topical, Injection and Inhalation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Spain 15-Year Perspective for Anti-Inflammatory Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Injection and Inhalation for the Years 2015, 2025 & 2030
    • TABLE 176: Spain Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Spain Historic Review for Anti-Inflammatory Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Spain 15-Year Perspective for Anti-Inflammatory Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 179: Russia Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Drug Type - Nonsteroidal Anti-inflammatory Drugs, Immune Selective Anti-inflammatory Derivatives, Anti-inflammatory Biologics and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Russia Historic Review for Anti-Inflammatory Drugs by Drug Type - Nonsteroidal Anti-inflammatory Drugs, Immune Selective Anti-inflammatory Derivatives, Anti-inflammatory Biologics and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Russia 15-Year Perspective for Anti-Inflammatory Drugs by Drug Type - Percentage Breakdown of Value Sales for Nonsteroidal Anti-inflammatory Drugs, Immune Selective Anti-inflammatory Derivatives, Anti-inflammatory Biologics and Corticosteroids for the Years 2015, 2025 & 2030
    • TABLE 182: Russia Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Application - Other Applications, Arthritis, Chronic Obstructive Pulmonary Disease, Multiple Sclerosis, Inflammatory Bowel Disease and Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Russia Historic Review for Anti-Inflammatory Drugs by Application - Other Applications, Arthritis, Chronic Obstructive Pulmonary Disease, Multiple Sclerosis, Inflammatory Bowel Disease and Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Russia 15-Year Perspective for Anti-Inflammatory Drugs by Application - Percentage Breakdown of Value Sales for Other Applications, Arthritis, Chronic Obstructive Pulmonary Disease, Multiple Sclerosis, Inflammatory Bowel Disease and Gout for the Years 2015, 2025 & 2030
    • TABLE 185: Russia Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Administration Route - Oral, Topical, Injection and Inhalation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Russia Historic Review for Anti-Inflammatory Drugs by Administration Route - Oral, Topical, Injection and Inhalation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Russia 15-Year Perspective for Anti-Inflammatory Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Injection and Inhalation for the Years 2015, 2025 & 2030
    • TABLE 188: Russia Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Russia Historic Review for Anti-Inflammatory Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Russia 15-Year Perspective for Anti-Inflammatory Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 191: Rest of Europe Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Drug Type - Nonsteroidal Anti-inflammatory Drugs, Immune Selective Anti-inflammatory Derivatives, Anti-inflammatory Biologics and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of Europe Historic Review for Anti-Inflammatory Drugs by Drug Type - Nonsteroidal Anti-inflammatory Drugs, Immune Selective Anti-inflammatory Derivatives, Anti-inflammatory Biologics and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Rest of Europe 15-Year Perspective for Anti-Inflammatory Drugs by Drug Type - Percentage Breakdown of Value Sales for Nonsteroidal Anti-inflammatory Drugs, Immune Selective Anti-inflammatory Derivatives, Anti-inflammatory Biologics and Corticosteroids for the Years 2015, 2025 & 2030
    • TABLE 194: Rest of Europe Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Application - Other Applications, Arthritis, Chronic Obstructive Pulmonary Disease, Multiple Sclerosis, Inflammatory Bowel Disease and Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Europe Historic Review for Anti-Inflammatory Drugs by Application - Other Applications, Arthritis, Chronic Obstructive Pulmonary Disease, Multiple Sclerosis, Inflammatory Bowel Disease and Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Rest of Europe 15-Year Perspective for Anti-Inflammatory Drugs by Application - Percentage Breakdown of Value Sales for Other Applications, Arthritis, Chronic Obstructive Pulmonary Disease, Multiple Sclerosis, Inflammatory Bowel Disease and Gout for the Years 2015, 2025 & 2030
    • TABLE 197: Rest of Europe Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Administration Route - Oral, Topical, Injection and Inhalation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Europe Historic Review for Anti-Inflammatory Drugs by Administration Route - Oral, Topical, Injection and Inhalation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Rest of Europe 15-Year Perspective for Anti-Inflammatory Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Injection and Inhalation for the Years 2015, 2025 & 2030
    • TABLE 200: Rest of Europe Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Europe Historic Review for Anti-Inflammatory Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Rest of Europe 15-Year Perspective for Anti-Inflammatory Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Anti-Inflammatory Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 203: Asia-Pacific Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 204: Asia-Pacific Historic Review for Anti-Inflammatory Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Asia-Pacific 15-Year Perspective for Anti-Inflammatory Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 206: Asia-Pacific Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Drug Type - Nonsteroidal Anti-inflammatory Drugs, Immune Selective Anti-inflammatory Derivatives, Anti-inflammatory Biologics and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Asia-Pacific Historic Review for Anti-Inflammatory Drugs by Drug Type - Nonsteroidal Anti-inflammatory Drugs, Immune Selective Anti-inflammatory Derivatives, Anti-inflammatory Biologics and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Asia-Pacific 15-Year Perspective for Anti-Inflammatory Drugs by Drug Type - Percentage Breakdown of Value Sales for Nonsteroidal Anti-inflammatory Drugs, Immune Selective Anti-inflammatory Derivatives, Anti-inflammatory Biologics and Corticosteroids for the Years 2015, 2025 & 2030
    • TABLE 209: Asia-Pacific Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Application - Other Applications, Arthritis, Chronic Obstructive Pulmonary Disease, Multiple Sclerosis, Inflammatory Bowel Disease and Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Asia-Pacific Historic Review for Anti-Inflammatory Drugs by Application - Other Applications, Arthritis, Chronic Obstructive Pulmonary Disease, Multiple Sclerosis, Inflammatory Bowel Disease and Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Asia-Pacific 15-Year Perspective for Anti-Inflammatory Drugs by Application - Percentage Breakdown of Value Sales for Other Applications, Arthritis, Chronic Obstructive Pulmonary Disease, Multiple Sclerosis, Inflammatory Bowel Disease and Gout for the Years 2015, 2025 & 2030
    • TABLE 212: Asia-Pacific Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Administration Route - Oral, Topical, Injection and Inhalation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Asia-Pacific Historic Review for Anti-Inflammatory Drugs by Administration Route - Oral, Topical, Injection and Inhalation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Asia-Pacific 15-Year Perspective for Anti-Inflammatory Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Injection and Inhalation for the Years 2015, 2025 & 2030
    • TABLE 215: Asia-Pacific Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Asia-Pacific Historic Review for Anti-Inflammatory Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: Asia-Pacific 15-Year Perspective for Anti-Inflammatory Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Anti-Inflammatory Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 218: Australia Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Drug Type - Nonsteroidal Anti-inflammatory Drugs, Immune Selective Anti-inflammatory Derivatives, Anti-inflammatory Biologics and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Australia Historic Review for Anti-Inflammatory Drugs by Drug Type - Nonsteroidal Anti-inflammatory Drugs, Immune Selective Anti-inflammatory Derivatives, Anti-inflammatory Biologics and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 220: Australia 15-Year Perspective for Anti-Inflammatory Drugs by Drug Type - Percentage Breakdown of Value Sales for Nonsteroidal Anti-inflammatory Drugs, Immune Selective Anti-inflammatory Derivatives, Anti-inflammatory Biologics and Corticosteroids for the Years 2015, 2025 & 2030
    • TABLE 221: Australia Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Application - Other Applications, Arthritis, Chronic Obstructive Pulmonary Disease, Multiple Sclerosis, Inflammatory Bowel Disease and Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Australia Historic Review for Anti-Inflammatory Drugs by Application - Other Applications, Arthritis, Chronic Obstructive Pulmonary Disease, Multiple Sclerosis, Inflammatory Bowel Disease and Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 223: Australia 15-Year Perspective for Anti-Inflammatory Drugs by Application - Percentage Breakdown of Value Sales for Other Applications, Arthritis, Chronic Obstructive Pulmonary Disease, Multiple Sclerosis, Inflammatory Bowel Disease and Gout for the Years 2015, 2025 & 2030
    • TABLE 224: Australia Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Administration Route - Oral, Topical, Injection and Inhalation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Australia Historic Review for Anti-Inflammatory Drugs by Administration Route - Oral, Topical, Injection and Inhalation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 226: Australia 15-Year Perspective for Anti-Inflammatory Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Injection and Inhalation for the Years 2015, 2025 & 2030
    • TABLE 227: Australia Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Australia Historic Review for Anti-Inflammatory Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 229: Australia 15-Year Perspective for Anti-Inflammatory Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • INDIA
    • Anti-Inflammatory Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 230: India Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Drug Type - Nonsteroidal Anti-inflammatory Drugs, Immune Selective Anti-inflammatory Derivatives, Anti-inflammatory Biologics and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: India Historic Review for Anti-Inflammatory Drugs by Drug Type - Nonsteroidal Anti-inflammatory Drugs, Immune Selective Anti-inflammatory Derivatives, Anti-inflammatory Biologics and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 232: India 15-Year Perspective for Anti-Inflammatory Drugs by Drug Type - Percentage Breakdown of Value Sales for Nonsteroidal Anti-inflammatory Drugs, Immune Selective Anti-inflammatory Derivatives, Anti-inflammatory Biologics and Corticosteroids for the Years 2015, 2025 & 2030
    • TABLE 233: India Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Application - Other Applications, Arthritis, Chronic Obstructive Pulmonary Disease, Multiple Sclerosis, Inflammatory Bowel Disease and Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: India Historic Review for Anti-Inflammatory Drugs by Application - Other Applications, Arthritis, Chronic Obstructive Pulmonary Disease, Multiple Sclerosis, Inflammatory Bowel Disease and Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 235: India 15-Year Perspective for Anti-Inflammatory Drugs by Application - Percentage Breakdown of Value Sales for Other Applications, Arthritis, Chronic Obstructive Pulmonary Disease, Multiple Sclerosis, Inflammatory Bowel Disease and Gout for the Years 2015, 2025 & 2030
    • TABLE 236: India Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Administration Route - Oral, Topical, Injection and Inhalation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: India Historic Review for Anti-Inflammatory Drugs by Administration Route - Oral, Topical, Injection and Inhalation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 238: India 15-Year Perspective for Anti-Inflammatory Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Injection and Inhalation for the Years 2015, 2025 & 2030
    • TABLE 239: India Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 240: India Historic Review for Anti-Inflammatory Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 241: India 15-Year Perspective for Anti-Inflammatory Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 242: South Korea Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Drug Type - Nonsteroidal Anti-inflammatory Drugs, Immune Selective Anti-inflammatory Derivatives, Anti-inflammatory Biologics and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: South Korea Historic Review for Anti-Inflammatory Drugs by Drug Type - Nonsteroidal Anti-inflammatory Drugs, Immune Selective Anti-inflammatory Derivatives, Anti-inflammatory Biologics and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 244: South Korea 15-Year Perspective for Anti-Inflammatory Drugs by Drug Type - Percentage Breakdown of Value Sales for Nonsteroidal Anti-inflammatory Drugs, Immune Selective Anti-inflammatory Derivatives, Anti-inflammatory Biologics and Corticosteroids for the Years 2015, 2025 & 2030
    • TABLE 245: South Korea Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Application - Other Applications, Arthritis, Chronic Obstructive Pulmonary Disease, Multiple Sclerosis, Inflammatory Bowel Disease and Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: South Korea Historic Review for Anti-Inflammatory Drugs by Application - Other Applications, Arthritis, Chronic Obstructive Pulmonary Disease, Multiple Sclerosis, Inflammatory Bowel Disease and Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 247: South Korea 15-Year Perspective for Anti-Inflammatory Drugs by Application - Percentage Breakdown of Value Sales for Other Applications, Arthritis, Chronic Obstructive Pulmonary Disease, Multiple Sclerosis, Inflammatory Bowel Disease and Gout for the Years 2015, 2025 & 2030
    • TABLE 248: South Korea Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Administration Route - Oral, Topical, Injection and Inhalation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: South Korea Historic Review for Anti-Inflammatory Drugs by Administration Route - Oral, Topical, Injection and Inhalation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 250: South Korea 15-Year Perspective for Anti-Inflammatory Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Injection and Inhalation for the Years 2015, 2025 & 2030
    • TABLE 251: South Korea Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: South Korea Historic Review for Anti-Inflammatory Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 253: South Korea 15-Year Perspective for Anti-Inflammatory Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 254: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Drug Type - Nonsteroidal Anti-inflammatory Drugs, Immune Selective Anti-inflammatory Derivatives, Anti-inflammatory Biologics and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Rest of Asia-Pacific Historic Review for Anti-Inflammatory Drugs by Drug Type - Nonsteroidal Anti-inflammatory Drugs, Immune Selective Anti-inflammatory Derivatives, Anti-inflammatory Biologics and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 256: Rest of Asia-Pacific 15-Year Perspective for Anti-Inflammatory Drugs by Drug Type - Percentage Breakdown of Value Sales for Nonsteroidal Anti-inflammatory Drugs, Immune Selective Anti-inflammatory Derivatives, Anti-inflammatory Biologics and Corticosteroids for the Years 2015, 2025 & 2030
    • TABLE 257: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Application - Other Applications, Arthritis, Chronic Obstructive Pulmonary Disease, Multiple Sclerosis, Inflammatory Bowel Disease and Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Rest of Asia-Pacific Historic Review for Anti-Inflammatory Drugs by Application - Other Applications, Arthritis, Chronic Obstructive Pulmonary Disease, Multiple Sclerosis, Inflammatory Bowel Disease and Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 259: Rest of Asia-Pacific 15-Year Perspective for Anti-Inflammatory Drugs by Application - Percentage Breakdown of Value Sales for Other Applications, Arthritis, Chronic Obstructive Pulmonary Disease, Multiple Sclerosis, Inflammatory Bowel Disease and Gout for the Years 2015, 2025 & 2030
    • TABLE 260: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Administration Route - Oral, Topical, Injection and Inhalation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Rest of Asia-Pacific Historic Review for Anti-Inflammatory Drugs by Administration Route - Oral, Topical, Injection and Inhalation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 262: Rest of Asia-Pacific 15-Year Perspective for Anti-Inflammatory Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Injection and Inhalation for the Years 2015, 2025 & 2030
    • TABLE 263: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Rest of Asia-Pacific Historic Review for Anti-Inflammatory Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 265: Rest of Asia-Pacific 15-Year Perspective for Anti-Inflammatory Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Anti-Inflammatory Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 266: Latin America Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 267: Latin America Historic Review for Anti-Inflammatory Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 268: Latin America 15-Year Perspective for Anti-Inflammatory Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 269: Latin America Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Drug Type - Nonsteroidal Anti-inflammatory Drugs, Immune Selective Anti-inflammatory Derivatives, Anti-inflammatory Biologics and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Latin America Historic Review for Anti-Inflammatory Drugs by Drug Type - Nonsteroidal Anti-inflammatory Drugs, Immune Selective Anti-inflammatory Derivatives, Anti-inflammatory Biologics and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 271: Latin America 15-Year Perspective for Anti-Inflammatory Drugs by Drug Type - Percentage Breakdown of Value Sales for Nonsteroidal Anti-inflammatory Drugs, Immune Selective Anti-inflammatory Derivatives, Anti-inflammatory Biologics and Corticosteroids for the Years 2015, 2025 & 2030
    • TABLE 272: Latin America Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Application - Other Applications, Arthritis, Chronic Obstructive Pulmonary Disease, Multiple Sclerosis, Inflammatory Bowel Disease and Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Latin America Historic Review for Anti-Inflammatory Drugs by Application - Other Applications, Arthritis, Chronic Obstructive Pulmonary Disease, Multiple Sclerosis, Inflammatory Bowel Disease and Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 274: Latin America 15-Year Perspective for Anti-Inflammatory Drugs by Application - Percentage Breakdown of Value Sales for Other Applications, Arthritis, Chronic Obstructive Pulmonary Disease, Multiple Sclerosis, Inflammatory Bowel Disease and Gout for the Years 2015, 2025 & 2030
    • TABLE 275: Latin America Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Administration Route - Oral, Topical, Injection and Inhalation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Latin America Historic Review for Anti-Inflammatory Drugs by Administration Route - Oral, Topical, Injection and Inhalation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 277: Latin America 15-Year Perspective for Anti-Inflammatory Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Injection and Inhalation for the Years 2015, 2025 & 2030
    • TABLE 278: Latin America Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Latin America Historic Review for Anti-Inflammatory Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 280: Latin America 15-Year Perspective for Anti-Inflammatory Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 281: Argentina Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Drug Type - Nonsteroidal Anti-inflammatory Drugs, Immune Selective Anti-inflammatory Derivatives, Anti-inflammatory Biologics and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Argentina Historic Review for Anti-Inflammatory Drugs by Drug Type - Nonsteroidal Anti-inflammatory Drugs, Immune Selective Anti-inflammatory Derivatives, Anti-inflammatory Biologics and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 283: Argentina 15-Year Perspective for Anti-Inflammatory Drugs by Drug Type - Percentage Breakdown of Value Sales for Nonsteroidal Anti-inflammatory Drugs, Immune Selective Anti-inflammatory Derivatives, Anti-inflammatory Biologics and Corticosteroids for the Years 2015, 2025 & 2030
    • TABLE 284: Argentina Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Application - Other Applications, Arthritis, Chronic Obstructive Pulmonary Disease, Multiple Sclerosis, Inflammatory Bowel Disease and Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Argentina Historic Review for Anti-Inflammatory Drugs by Application - Other Applications, Arthritis, Chronic Obstructive Pulmonary Disease, Multiple Sclerosis, Inflammatory Bowel Disease and Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 286: Argentina 15-Year Perspective for Anti-Inflammatory Drugs by Application - Percentage Breakdown of Value Sales for Other Applications, Arthritis, Chronic Obstructive Pulmonary Disease, Multiple Sclerosis, Inflammatory Bowel Disease and Gout for the Years 2015, 2025 & 2030
    • TABLE 287: Argentina Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Administration Route - Oral, Topical, Injection and Inhalation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Argentina Historic Review for Anti-Inflammatory Drugs by Administration Route - Oral, Topical, Injection and Inhalation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 289: Argentina 15-Year Perspective for Anti-Inflammatory Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Injection and Inhalation for the Years 2015, 2025 & 2030
    • TABLE 290: Argentina Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Argentina Historic Review for Anti-Inflammatory Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 292: Argentina 15-Year Perspective for Anti-Inflammatory Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 293: Brazil Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Drug Type - Nonsteroidal Anti-inflammatory Drugs, Immune Selective Anti-inflammatory Derivatives, Anti-inflammatory Biologics and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Brazil Historic Review for Anti-Inflammatory Drugs by Drug Type - Nonsteroidal Anti-inflammatory Drugs, Immune Selective Anti-inflammatory Derivatives, Anti-inflammatory Biologics and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 295: Brazil 15-Year Perspective for Anti-Inflammatory Drugs by Drug Type - Percentage Breakdown of Value Sales for Nonsteroidal Anti-inflammatory Drugs, Immune Selective Anti-inflammatory Derivatives, Anti-inflammatory Biologics and Corticosteroids for the Years 2015, 2025 & 2030
    • TABLE 296: Brazil Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Application - Other Applications, Arthritis, Chronic Obstructive Pulmonary Disease, Multiple Sclerosis, Inflammatory Bowel Disease and Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Brazil Historic Review for Anti-Inflammatory Drugs by Application - Other Applications, Arthritis, Chronic Obstructive Pulmonary Disease, Multiple Sclerosis, Inflammatory Bowel Disease and Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 298: Brazil 15-Year Perspective for Anti-Inflammatory Drugs by Application - Percentage Breakdown of Value Sales for Other Applications, Arthritis, Chronic Obstructive Pulmonary Disease, Multiple Sclerosis, Inflammatory Bowel Disease and Gout for the Years 2015, 2025 & 2030
    • TABLE 299: Brazil Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Administration Route - Oral, Topical, Injection and Inhalation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Brazil Historic Review for Anti-Inflammatory Drugs by Administration Route - Oral, Topical, Injection and Inhalation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 301: Brazil 15-Year Perspective for Anti-Inflammatory Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Injection and Inhalation for the Years 2015, 2025 & 2030
    • TABLE 302: Brazil Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Brazil Historic Review for Anti-Inflammatory Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 304: Brazil 15-Year Perspective for Anti-Inflammatory Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 305: Mexico Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Drug Type - Nonsteroidal Anti-inflammatory Drugs, Immune Selective Anti-inflammatory Derivatives, Anti-inflammatory Biologics and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Mexico Historic Review for Anti-Inflammatory Drugs by Drug Type - Nonsteroidal Anti-inflammatory Drugs, Immune Selective Anti-inflammatory Derivatives, Anti-inflammatory Biologics and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 307: Mexico 15-Year Perspective for Anti-Inflammatory Drugs by Drug Type - Percentage Breakdown of Value Sales for Nonsteroidal Anti-inflammatory Drugs, Immune Selective Anti-inflammatory Derivatives, Anti-inflammatory Biologics and Corticosteroids for the Years 2015, 2025 & 2030
    • TABLE 308: Mexico Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Application - Other Applications, Arthritis, Chronic Obstructive Pulmonary Disease, Multiple Sclerosis, Inflammatory Bowel Disease and Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Mexico Historic Review for Anti-Inflammatory Drugs by Application - Other Applications, Arthritis, Chronic Obstructive Pulmonary Disease, Multiple Sclerosis, Inflammatory Bowel Disease and Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 310: Mexico 15-Year Perspective for Anti-Inflammatory Drugs by Application - Percentage Breakdown of Value Sales for Other Applications, Arthritis, Chronic Obstructive Pulmonary Disease, Multiple Sclerosis, Inflammatory Bowel Disease and Gout for the Years 2015, 2025 & 2030
    • TABLE 311: Mexico Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Administration Route - Oral, Topical, Injection and Inhalation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 312: Mexico Historic Review for Anti-Inflammatory Drugs by Administration Route - Oral, Topical, Injection and Inhalation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 313: Mexico 15-Year Perspective for Anti-Inflammatory Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Injection and Inhalation for the Years 2015, 2025 & 2030
    • TABLE 314: Mexico Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 315: Mexico Historic Review for Anti-Inflammatory Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 316: Mexico 15-Year Perspective for Anti-Inflammatory Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 317: Rest of Latin America Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Drug Type - Nonsteroidal Anti-inflammatory Drugs, Immune Selective Anti-inflammatory Derivatives, Anti-inflammatory Biologics and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 318: Rest of Latin America Historic Review for Anti-Inflammatory Drugs by Drug Type - Nonsteroidal Anti-inflammatory Drugs, Immune Selective Anti-inflammatory Derivatives, Anti-inflammatory Biologics and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 319: Rest of Latin America 15-Year Perspective for Anti-Inflammatory Drugs by Drug Type - Percentage Breakdown of Value Sales for Nonsteroidal Anti-inflammatory Drugs, Immune Selective Anti-inflammatory Derivatives, Anti-inflammatory Biologics and Corticosteroids for the Years 2015, 2025 & 2030
    • TABLE 320: Rest of Latin America Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Application - Other Applications, Arthritis, Chronic Obstructive Pulmonary Disease, Multiple Sclerosis, Inflammatory Bowel Disease and Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 321: Rest of Latin America Historic Review for Anti-Inflammatory Drugs by Application - Other Applications, Arthritis, Chronic Obstructive Pulmonary Disease, Multiple Sclerosis, Inflammatory Bowel Disease and Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 322: Rest of Latin America 15-Year Perspective for Anti-Inflammatory Drugs by Application - Percentage Breakdown of Value Sales for Other Applications, Arthritis, Chronic Obstructive Pulmonary Disease, Multiple Sclerosis, Inflammatory Bowel Disease and Gout for the Years 2015, 2025 & 2030
    • TABLE 323: Rest of Latin America Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Administration Route - Oral, Topical, Injection and Inhalation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 324: Rest of Latin America Historic Review for Anti-Inflammatory Drugs by Administration Route - Oral, Topical, Injection and Inhalation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 325: Rest of Latin America 15-Year Perspective for Anti-Inflammatory Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Injection and Inhalation for the Years 2015, 2025 & 2030
    • TABLE 326: Rest of Latin America Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 327: Rest of Latin America Historic Review for Anti-Inflammatory Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 328: Rest of Latin America 15-Year Perspective for Anti-Inflammatory Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Anti-Inflammatory Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 329: Middle East Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 330: Middle East Historic Review for Anti-Inflammatory Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 331: Middle East 15-Year Perspective for Anti-Inflammatory Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 332: Middle East Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Drug Type - Nonsteroidal Anti-inflammatory Drugs, Immune Selective Anti-inflammatory Derivatives, Anti-inflammatory Biologics and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 333: Middle East Historic Review for Anti-Inflammatory Drugs by Drug Type - Nonsteroidal Anti-inflammatory Drugs, Immune Selective Anti-inflammatory Derivatives, Anti-inflammatory Biologics and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 334: Middle East 15-Year Perspective for Anti-Inflammatory Drugs by Drug Type - Percentage Breakdown of Value Sales for Nonsteroidal Anti-inflammatory Drugs, Immune Selective Anti-inflammatory Derivatives, Anti-inflammatory Biologics and Corticosteroids for the Years 2015, 2025 & 2030
    • TABLE 335: Middle East Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Application - Other Applications, Arthritis, Chronic Obstructive Pulmonary Disease, Multiple Sclerosis, Inflammatory Bowel Disease and Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 336: Middle East Historic Review for Anti-Inflammatory Drugs by Application - Other Applications, Arthritis, Chronic Obstructive Pulmonary Disease, Multiple Sclerosis, Inflammatory Bowel Disease and Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 337: Middle East 15-Year Perspective for Anti-Inflammatory Drugs by Application - Percentage Breakdown of Value Sales for Other Applications, Arthritis, Chronic Obstructive Pulmonary Disease, Multiple Sclerosis, Inflammatory Bowel Disease and Gout for the Years 2015, 2025 & 2030
    • TABLE 338: Middle East Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Administration Route - Oral, Topical, Injection and Inhalation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 339: Middle East Historic Review for Anti-Inflammatory Drugs by Administration Route - Oral, Topical, Injection and Inhalation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 340: Middle East 15-Year Perspective for Anti-Inflammatory Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Injection and Inhalation for the Years 2015, 2025 & 2030
    • TABLE 341: Middle East Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 342: Middle East Historic Review for Anti-Inflammatory Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 343: Middle East 15-Year Perspective for Anti-Inflammatory Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 344: Iran Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Drug Type - Nonsteroidal Anti-inflammatory Drugs, Immune Selective Anti-inflammatory Derivatives, Anti-inflammatory Biologics and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 345: Iran Historic Review for Anti-Inflammatory Drugs by Drug Type - Nonsteroidal Anti-inflammatory Drugs, Immune Selective Anti-inflammatory Derivatives, Anti-inflammatory Biologics and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 346: Iran 15-Year Perspective for Anti-Inflammatory Drugs by Drug Type - Percentage Breakdown of Value Sales for Nonsteroidal Anti-inflammatory Drugs, Immune Selective Anti-inflammatory Derivatives, Anti-inflammatory Biologics and Corticosteroids for the Years 2015, 2025 & 2030
    • TABLE 347: Iran Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Application - Other Applications, Arthritis, Chronic Obstructive Pulmonary Disease, Multiple Sclerosis, Inflammatory Bowel Disease and Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 348: Iran Historic Review for Anti-Inflammatory Drugs by Application - Other Applications, Arthritis, Chronic Obstructive Pulmonary Disease, Multiple Sclerosis, Inflammatory Bowel Disease and Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 349: Iran 15-Year Perspective for Anti-Inflammatory Drugs by Application - Percentage Breakdown of Value Sales for Other Applications, Arthritis, Chronic Obstructive Pulmonary Disease, Multiple Sclerosis, Inflammatory Bowel Disease and Gout for the Years 2015, 2025 & 2030
    • TABLE 350: Iran Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Administration Route - Oral, Topical, Injection and Inhalation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 351: Iran Historic Review for Anti-Inflammatory Drugs by Administration Route - Oral, Topical, Injection and Inhalation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 352: Iran 15-Year Perspective for Anti-Inflammatory Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Injection and Inhalation for the Years 2015, 2025 & 2030
    • TABLE 353: Iran Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 354: Iran Historic Review for Anti-Inflammatory Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 355: Iran 15-Year Perspective for Anti-Inflammatory Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 356: Israel Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Drug Type - Nonsteroidal Anti-inflammatory Drugs, Immune Selective Anti-inflammatory Derivatives, Anti-inflammatory Biologics and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 357: Israel Historic Review for Anti-Inflammatory Drugs by Drug Type - Nonsteroidal Anti-inflammatory Drugs, Immune Selective Anti-inflammatory Derivatives, Anti-inflammatory Biologics and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 358: Israel 15-Year Perspective for Anti-Inflammatory Drugs by Drug Type - Percentage Breakdown of Value Sales for Nonsteroidal Anti-inflammatory Drugs, Immune Selective Anti-inflammatory Derivatives, Anti-inflammatory Biologics and Corticosteroids for the Years 2015, 2025 & 2030
    • TABLE 359: Israel Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Application - Other Applications, Arthritis, Chronic Obstructive Pulmonary Disease, Multiple Sclerosis, Inflammatory Bowel Disease and Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 360: Israel Historic Review for Anti-Inflammatory Drugs by Application - Other Applications, Arthritis, Chronic Obstructive Pulmonary Disease, Multiple Sclerosis, Inflammatory Bowel Disease and Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 361: Israel 15-Year Perspective for Anti-Inflammatory Drugs by Application - Percentage Breakdown of Value Sales for Other Applications, Arthritis, Chronic Obstructive Pulmonary Disease, Multiple Sclerosis, Inflammatory Bowel Disease and Gout for the Years 2015, 2025 & 2030
    • TABLE 362: Israel Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Administration Route - Oral, Topical, Injection and Inhalation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 363: Israel Historic Review for Anti-Inflammatory Drugs by Administration Route - Oral, Topical, Injection and Inhalation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 364: Israel 15-Year Perspective for Anti-Inflammatory Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Injection and Inhalation for the Years 2015, 2025 & 2030
    • TABLE 365: Israel Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 366: Israel Historic Review for Anti-Inflammatory Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 367: Israel 15-Year Perspective for Anti-Inflammatory Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 368: Saudi Arabia Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Drug Type - Nonsteroidal Anti-inflammatory Drugs, Immune Selective Anti-inflammatory Derivatives, Anti-inflammatory Biologics and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 369: Saudi Arabia Historic Review for Anti-Inflammatory Drugs by Drug Type - Nonsteroidal Anti-inflammatory Drugs, Immune Selective Anti-inflammatory Derivatives, Anti-inflammatory Biologics and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 370: Saudi Arabia 15-Year Perspective for Anti-Inflammatory Drugs by Drug Type - Percentage Breakdown of Value Sales for Nonsteroidal Anti-inflammatory Drugs, Immune Selective Anti-inflammatory Derivatives, Anti-inflammatory Biologics and Corticosteroids for the Years 2015, 2025 & 2030
    • TABLE 371: Saudi Arabia Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Application - Other Applications, Arthritis, Chronic Obstructive Pulmonary Disease, Multiple Sclerosis, Inflammatory Bowel Disease and Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 372: Saudi Arabia Historic Review for Anti-Inflammatory Drugs by Application - Other Applications, Arthritis, Chronic Obstructive Pulmonary Disease, Multiple Sclerosis, Inflammatory Bowel Disease and Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 373: Saudi Arabia 15-Year Perspective for Anti-Inflammatory Drugs by Application - Percentage Breakdown of Value Sales for Other Applications, Arthritis, Chronic Obstructive Pulmonary Disease, Multiple Sclerosis, Inflammatory Bowel Disease and Gout for the Years 2015, 2025 & 2030
    • TABLE 374: Saudi Arabia Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Administration Route - Oral, Topical, Injection and Inhalation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 375: Saudi Arabia Historic Review for Anti-Inflammatory Drugs by Administration Route - Oral, Topical, Injection and Inhalation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 376: Saudi Arabia 15-Year Perspective for Anti-Inflammatory Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Injection and Inhalation for the Years 2015, 2025 & 2030
    • TABLE 377: Saudi Arabia Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 378: Saudi Arabia Historic Review for Anti-Inflammatory Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 379: Saudi Arabia 15-Year Perspective for Anti-Inflammatory Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 380: UAE Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Drug Type - Nonsteroidal Anti-inflammatory Drugs, Immune Selective Anti-inflammatory Derivatives, Anti-inflammatory Biologics and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 381: UAE Historic Review for Anti-Inflammatory Drugs by Drug Type - Nonsteroidal Anti-inflammatory Drugs, Immune Selective Anti-inflammatory Derivatives, Anti-inflammatory Biologics and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 382: UAE 15-Year Perspective for Anti-Inflammatory Drugs by Drug Type - Percentage Breakdown of Value Sales for Nonsteroidal Anti-inflammatory Drugs, Immune Selective Anti-inflammatory Derivatives, Anti-inflammatory Biologics and Corticosteroids for the Years 2015, 2025 & 2030
    • TABLE 383: UAE Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Application - Other Applications, Arthritis, Chronic Obstructive Pulmonary Disease, Multiple Sclerosis, Inflammatory Bowel Disease and Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 384: UAE Historic Review for Anti-Inflammatory Drugs by Application - Other Applications, Arthritis, Chronic Obstructive Pulmonary Disease, Multiple Sclerosis, Inflammatory Bowel Disease and Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 385: UAE 15-Year Perspective for Anti-Inflammatory Drugs by Application - Percentage Breakdown of Value Sales for Other Applications, Arthritis, Chronic Obstructive Pulmonary Disease, Multiple Sclerosis, Inflammatory Bowel Disease and Gout for the Years 2015, 2025 & 2030
    • TABLE 386: UAE Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Administration Route - Oral, Topical, Injection and Inhalation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 387: UAE Historic Review for Anti-Inflammatory Drugs by Administration Route - Oral, Topical, Injection and Inhalation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 388: UAE 15-Year Perspective for Anti-Inflammatory Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Injection and Inhalation for the Years 2015, 2025 & 2030
    • TABLE 389: UAE Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 390: UAE Historic Review for Anti-Inflammatory Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 391: UAE 15-Year Perspective for Anti-Inflammatory Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 392: Rest of Middle East Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Drug Type - Nonsteroidal Anti-inflammatory Drugs, Immune Selective Anti-inflammatory Derivatives, Anti-inflammatory Biologics and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 393: Rest of Middle East Historic Review for Anti-Inflammatory Drugs by Drug Type - Nonsteroidal Anti-inflammatory Drugs, Immune Selective Anti-inflammatory Derivatives, Anti-inflammatory Biologics and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 394: Rest of Middle East 15-Year Perspective for Anti-Inflammatory Drugs by Drug Type - Percentage Breakdown of Value Sales for Nonsteroidal Anti-inflammatory Drugs, Immune Selective Anti-inflammatory Derivatives, Anti-inflammatory Biologics and Corticosteroids for the Years 2015, 2025 & 2030
    • TABLE 395: Rest of Middle East Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Application - Other Applications, Arthritis, Chronic Obstructive Pulmonary Disease, Multiple Sclerosis, Inflammatory Bowel Disease and Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 396: Rest of Middle East Historic Review for Anti-Inflammatory Drugs by Application - Other Applications, Arthritis, Chronic Obstructive Pulmonary Disease, Multiple Sclerosis, Inflammatory Bowel Disease and Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 397: Rest of Middle East 15-Year Perspective for Anti-Inflammatory Drugs by Application - Percentage Breakdown of Value Sales for Other Applications, Arthritis, Chronic Obstructive Pulmonary Disease, Multiple Sclerosis, Inflammatory Bowel Disease and Gout for the Years 2015, 2025 & 2030
    • TABLE 398: Rest of Middle East Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Administration Route - Oral, Topical, Injection and Inhalation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 399: Rest of Middle East Historic Review for Anti-Inflammatory Drugs by Administration Route - Oral, Topical, Injection and Inhalation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 400: Rest of Middle East 15-Year Perspective for Anti-Inflammatory Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Injection and Inhalation for the Years 2015, 2025 & 2030
    • TABLE 401: Rest of Middle East Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 402: Rest of Middle East Historic Review for Anti-Inflammatory Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 403: Rest of Middle East 15-Year Perspective for Anti-Inflammatory Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • AFRICA
    • Anti-Inflammatory Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 404: Africa Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Drug Type - Nonsteroidal Anti-inflammatory Drugs, Immune Selective Anti-inflammatory Derivatives, Anti-inflammatory Biologics and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 405: Africa Historic Review for Anti-Inflammatory Drugs by Drug Type - Nonsteroidal Anti-inflammatory Drugs, Immune Selective Anti-inflammatory Derivatives, Anti-inflammatory Biologics and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 406: Africa 15-Year Perspective for Anti-Inflammatory Drugs by Drug Type - Percentage Breakdown of Value Sales for Nonsteroidal Anti-inflammatory Drugs, Immune Selective Anti-inflammatory Derivatives, Anti-inflammatory Biologics and Corticosteroids for the Years 2015, 2025 & 2030
    • TABLE 407: Africa Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Application - Other Applications, Arthritis, Chronic Obstructive Pulmonary Disease, Multiple Sclerosis, Inflammatory Bowel Disease and Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 408: Africa Historic Review for Anti-Inflammatory Drugs by Application - Other Applications, Arthritis, Chronic Obstructive Pulmonary Disease, Multiple Sclerosis, Inflammatory Bowel Disease and Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 409: Africa 15-Year Perspective for Anti-Inflammatory Drugs by Application - Percentage Breakdown of Value Sales for Other Applications, Arthritis, Chronic Obstructive Pulmonary Disease, Multiple Sclerosis, Inflammatory Bowel Disease and Gout for the Years 2015, 2025 & 2030
    • TABLE 410: Africa Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Administration Route - Oral, Topical, Injection and Inhalation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 411: Africa Historic Review for Anti-Inflammatory Drugs by Administration Route - Oral, Topical, Injection and Inhalation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 412: Africa 15-Year Perspective for Anti-Inflammatory Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Injection and Inhalation for the Years 2015, 2025 & 2030
    • TABLE 413: Africa Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 414: Africa Historic Review for Anti-Inflammatory Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 415: Africa 15-Year Perspective for Anti-Inflammatory Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제